Grant R. Wilkinson

Grant R. Wilkinson's AcademicInfluence.com Rankings

Grant R. Wilkinson

Medical

#1340

World Rank

#1667

Historical Rank

Gastroenterology

#14

World Rank

#14

Historical Rank

Pharmacology

#102

World Rank

#131

Historical Rank

medical Degrees

Grant R. Wilkinson

Philosophy

#4318

World Rank

#6792

Historical Rank

Logic

#1809

World Rank

#2652

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Grant R. Wilkinson's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Grant R. Wilkinson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Grant R. Wilkinson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A physiological approach to hepatic drug clearance (1975) (1860)
Drug metabolism and variability among patients in drug response. (2005) (1123)
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. (1998) (1106)
Identification of functionally variant MDR1 alleles among European Americans and African Americans (2001) (1037)
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. (1994) (961)
Lorazepam Is an Independent Risk Factor for Transitioning to Delirium in Intensive Care Unit Patients (2006) (875)
In vitro and in vivo drug interactions involving human CYP3A. (1998) (834)
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. (1994) (795)
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study (2004) (676)
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. (1975) (644)
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. (1999) (602)
Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism (1996) (599)
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (1985) (490)
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein (1999) (422)
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. (2000) (421)
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. (1999) (410)
Reduction of liver blood flow and propranolol metabolism by cimetidine. (1981) (396)
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans (2006) (386)
Clearance approaches in pharmacology. (1987) (364)
Genetic polymorphism of S-mephenytoin hydroxylation. (1989) (317)
Genetic variability in CYP3A5 and its possible consequences. (2004) (313)
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. (1977) (311)
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. (1985) (308)
Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism (1984) (297)
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. (1987) (290)
Commentary: a physiological approach to hepatic drug clearance. (1975) (279)
CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism (2000) (278)
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. (2003) (276)
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. (2005) (271)
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. (2001) (267)
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. (1999) (267)
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (2003) (258)
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. (2006) (241)
Effects of aging and liver disease on disposition of lorazepam (1978) (239)
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. (1976) (239)
Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. (1989) (229)
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. (1998) (226)
Altered Hepatic Blood Flow and Drug Disposition (1976) (206)
Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans (1996) (202)
Effect of fasting and obesity in humans on the 6‐hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity (1994) (201)
Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients (2003) (201)
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. (1999) (191)
Effects of age and cigarette smoking on propranolol disposition (1979) (190)
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities (1989) (188)
Increased toxicity and reduced clearance of lidocaine by cimetidine. (1982) (173)
Normal metabolism of morphine in cirrhosis. (1981) (171)
Biological determinants of propranolol disposition in man (1978) (166)
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. (1987) (166)
Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). (1978) (159)
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. (1980) (158)
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. (1984) (158)
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. (2006) (157)
Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms (1995) (155)
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man (1978) (148)
Direct measurement of propranolol bioavailability during accumulation to steady-state. (1978) (145)
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. (1984) (144)
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. (1974) (140)
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A (1999) (140)
Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. (1987) (136)
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. (2001) (132)
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men (1993) (130)
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination (1979) (127)
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. (1999) (126)
Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. (1999) (125)
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia (1978) (125)
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. (2009) (123)
Pharmacokinetics of drug disposition: hemodynamic considerations. (1975) (120)
Effects of route of administration and blood flow on hepatic drug elimination. (1975) (115)
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. (1998) (114)
The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. (1973) (112)
Interaction of quinidine with anticonvulsant drugs. (1976) (110)
The effect of cirrhosis on the disposition and elimination of meperidine in man (1974) (109)
Drug disposition and liver disease. (1975) (107)
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. (1984) (102)
Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives (1979) (102)
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. (1999) (101)
In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. (1996) (100)
Plasma and tissue binding considerations in drug disposition. (1983) (99)
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. (1985) (99)
Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 (1998) (99)
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. (1990) (98)
Effects of liver disease on drug disposition in man. (1976) (97)
Antiarrhythmic effects of a lidocaine congener, tocainide, 2‐amino‐2',6'‐propionoxylidide, in man (1976) (96)
Frequency distribution of dapsone N‐hydroxylase, a putative probe for P4503A4 activity, in a white population (1994) (93)
The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration (1978) (92)
Suppression of Ventricular Ectopic Depolarizations by Tocainide (1977) (91)
Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. (1988) (91)
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. (1977) (91)
Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. (1992) (90)
Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade (1984) (86)
The erythromycin breath test reflects P‐glycoprotein function independently of cytochrome P450 3A activity (2006) (85)
Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier (2006) (84)
Differences in plasma binding of drugs between Caucasians and Chinese subjects (1990) (84)
Erythrocyte uptake and plasma binding of di phenyl hydantoin (1974) (84)
Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. (1968) (83)
Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. (1989) (82)
Amiodarone dosing: a proposal based on its pharmacokinetics. (1983) (81)
Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. (1988) (80)
Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat. (1976) (76)
Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study (2006) (75)
CYP3A activity in European American and Japanese men using midazolam as an in vivo probe (2001) (75)
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP 3 A (1998) (73)
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. (1984) (72)
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. (1987) (70)
In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (2004) (69)
The contribution of N‐hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects (1990) (69)
Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. (1976) (69)
A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 (2003) (68)
Bupivacaine Levels in Plasma and Cerebrospinal Fluid Following Peridural Administration (1970) (67)
The effect of cirrhosis on the disposition and elimination of meperidine in man. (1975) (67)
MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study (2003) (67)
THE EFFECTS OF AGE AND LIVER DISEASE ON THE DISPOSITION AND ELIMINATION OF DIAZEPAM IN ADULT MAN (1976) (66)
The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog. (1978) (66)
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. (1999) (66)
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. (1999) (63)
Perfusion-limited effects of plasma drug binding on hepatic drug extraction (1976) (62)
Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. (1984) (62)
Co‐inheritance of the polymorphic metabolism of encainide and debrisoquin (1986) (61)
Effect of acute viral hepatitis in man on the disposition and elimination of meperidine. (1975) (61)
Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital (1986) (58)
Induction of propranolol metabolism by rifampicin. (1983) (57)
CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences (2004) (56)
Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (1996) (55)
The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver. (1973) (54)
Propranolol disposition in renal failure. (1980) (54)
Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. (1968) (54)
Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. (1996) (53)
Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. (1986) (53)
Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin (1990) (51)
Furosemide kinetics and dynamics in patients with cirrhosis (1986) (51)
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans (1991) (50)
Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques (2002) (50)
5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. (2004) (50)
Effect of heparin administration on plasma binding of benzodiazepines. (1980) (50)
Plasma binding of benzodiazepines in humans. (1979) (49)
Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. (1994) (48)
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. (2000) (48)
Sub-microgram estimation of morphine in biological fluids by gas-liquid chromatography. (1969) (47)
The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man (1978) (45)
Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. (1994) (45)
Effect of hypotension on liver blood flow and lidocaine disposition. (1982) (44)
Aging and benzodiazepine binding in the rat cerebral cortex. (1982) (44)
Dietary salt increases first‐pass elimination of oral quinidine (1997) (44)
Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans (1980) (42)
Disposition of diazepam in young and elderly subjects after acute and chronic dosing. (1996) (42)
S‐mephenytoin 4‐hydroxylase is inherited as an autosomal‐recessive trait in Japanese families (1987) (42)
The disposition of dapsone in cirrhosis (1992) (41)
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. (1999) (40)
Meperidine disposition in man: Influence of urinary pH and route of administration (1981) (40)
Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions (2004) (40)
Furosemide disposition in cirrhosis (1982) (40)
α2HS–Glycoprotein Is Expressed at High Concentration in Human Fetal Plasma and Cerebrospinal Fluid (1993) (40)
Reduction of liver plasma flow by caffeine and theophylline (1986) (38)
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine (1996) (38)
Genetically determined drug‐metabolizing activity and desipramine‐associated cardiotoxicity: A case report (1993) (37)
Drug Metabolites in Renal Failure (1981) (37)
The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. (1973) (37)
Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein (2008) (36)
Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. (1997) (34)
Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. (1986) (33)
Effects of age on meperidine disposition (1985) (33)
In vivo inhibition of human CYP1A2 activity by oltipraz (2001) (33)
Racial Differences in Drug Response (1989) (31)
Influence of urine pH and flow rate on the renal excretion of chlorpheniramine in man (1965) (31)
Disposition kinetics of encainide and metabolites. (1986) (30)
Influence of phenobarbital on factors responsible for hepatic clearance of indocyanine green in the rat: relative contributions of induction and altered liver blood flow. (1977) (29)
Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. (1994) (27)
Disposition of furosemide in functionally hepatectomized dogs. (1981) (27)
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination (1999) (27)
Drug metabolites in renal failure: pharmacokinetic and clinical implications. (1981) (26)
The GLC Separation of Amphetamine and Ephedrines as Pentafluorobenzamide Derivatives and Their Determination by Electron Capture Detection (1970) (26)
Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients. (2007) (26)
Gastric and biliary excretion of meperidine in man (1976) (26)
High fetal blood levels of mepivacaine and fetal bradycardia. (1968) (26)
Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. (1987) (25)
Encainide disposition in patients with chronic cirrhosis (1986) (25)
The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics. (1975) (25)
Drug metabolism and disposition : considerations in clinical pharmacology (1985) (24)
Encainide disposition in patients with renal failure (1986) (24)
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. (1989) (24)
Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects (2002) (24)
Urinary excretion of (—)‐methylephedrine, (—)‐ephedrine and (—)‐norephedrine in man (1965) (23)
A new method for constant plasma drug concentrations: application to lidocaine. (1984) (23)
Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. (1977) (22)
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism (1989) (22)
Diazepam disposition in mature and aged rabbits and rats. (1982) (22)
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. (1995) (21)
Drug distribution and renal excretion in the elderly. (1983) (21)
Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. (1994) (20)
Effect of acute alcohol ingestion on plasma pyridoxal 5'-phosphate. (1979) (19)
Delivery of anticonvulsant drug therapy in epileptic patients assessed by plasma level analyses (1974) (18)
The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. (1992) (18)
Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. (1997) (17)
GLC determination of papaverine in biological fluids. (1974) (17)
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. (2003) (17)
Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]. (1977) (17)
Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis (1997) (17)
Gas chromatographic determination of mepivacaine in capillary blood. (1969) (16)
Elevated Plasma Free Drug Concentrations of Propranolol and Diazepam During Cardiac Catheterization (1980) (16)
Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans * (2002) (16)
Racial differences in drug response. (1989) (15)
Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long‐term dosing (1983) (15)
The Relationship Between Cytochrome P4502E1 Activity and Plasma Fluoride Levels After Sevoflurane Anesthesia in Humans (1997) (15)
Identification and determination of ephedrine and its congeners in urine by gas chromatography (1965) (14)
Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. (1990) (13)
Geometric isomerization of doxepin during its N-demethylation in humans. (1991) (13)
No Evidence for In Vivo Enhanced Dissociation (1989) (13)
Chronic and severe phenobarbital intoxication in a child treated with primidone and diphenylhydantoin. (1973) (13)
alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid. (1993) (12)
In vivo and in vitro measurement of CYP2C19 activity. (1996) (12)
Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. (1999) (12)
Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride–induced disease (1992) (11)
CYP2E1 activity is not altered by influenza vaccination. (1996) (10)
Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. (1977) (10)
Cholestasis in transplant patients—what is the role of cyclosporin? (1992) (10)
Watercress inhibits human CYP2E1 activity in vivo as measured by chlorzoxazone 6‐hydroxylation (1996) (10)
The effects of ageing on the disposition of benzodiazepines in man (1979) (10)
Sedative Plasma Concentrations and Delirium Risk in Critical Illness (2018) (9)
Dietary Effects on Drug Metabolism (1995) (9)
Perfusion-limited of plasma drug binding on hepatic drug extraction. (1976) (8)
Hepatic tissue binding and the oral first-pass effect. (1984) (8)
Impaired elimination of meperidine in patients with liver disease. (1974) (8)
The determination of meperidine, noremeperidine and deuterated analogs in blood and plasma by gas chromatography mass spectrometry selected ion monitoring. (1980) (7)
Reduced levels of alpha-1-antitrypsin in children exposed to high levels of air pollution. (1993) (6)
Enantiospecific quantification of hexobarbital and its metabolites in biological fluids by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. (1991) (6)
Hepatic elimination in the rat of ditekiren (U-71038), a renin inhibitor pseudohexapeptide. (1993) (6)
Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man (1984) (5)
The application of clearance concepts to propranolol disposition in man. (1979) (5)
No effect of smoking on metabolism of chlordiazepoxide. (1979) (5)
The effect of heparin on benzodiazepine binding in plasma (1979) (5)
Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer. (1997) (5)
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. (1991) (5)
In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans (2001) (4)
Pharmacokinetic interpretation of dicloxacillin levels in serum after extravascular administration. (1969) (4)
Bladder cancer recurrence and its association with cytochrome P-450IID6 activity. (1992) (4)
Erythromycin breath test (multiple letters) (2000) (4)
The assessment of bioavailability in the presence of nonlinear elimination (1988) (4)
Observations on the gas chromatographic behaviour of some amines used in anorectic formulations. (1967) (4)
Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man. (1987) (3)
OATP and P‐glycoprotein mediate the uptake and excretion of fexofenadine (1999) (3)
High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. (1997) (3)
Acute Effects of Halothane Anesthesia on Arterial and Venous Concentrations of Propranolol in the Dog (1987) (3)
Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. (1996) (3)
Treatment of drug intoxication: a review of some scientific principles. (1970) (3)
Physiological factors affecting hepatic first-pass metabolism (1982) (3)
Identification and Functional Characterization of a New CYP 2 C 9 Variant ( CYP 2 C 9 * 51 ) Expressed among African Americans (2001) (2)
Proceedings: High-affinity hepatic microsomal binding of propranolol: its relationship to metabolism and to the first-pass effect. (1974) (2)
Proceedings: Presystemic hepatic elimination. (1974) (2)
New up-conversion luminescence in molecular cyano-substituted naphthylsalophen lanthanide(III) complexes. (2021) (2)
918 – EFFECT OF DRUG CONCENTRATION AND ENZYME INDUCERS ON INDOCYANINE GREEN CLEARANCE IN THE RAT (1977) (2)
2301 – AGE RELATED EFFECTS OF SMOKING ON ELIMINATION OF PROPRANOLOL (P) ANTIPYRINE (Ap) AND INDOCYANINE GREEN (ICG) (1978) (2)
Suppression ofVentricular Ectopic Depolarizations byTocainide (1977) (1)
Tariquidar (TAR, XR‐9576) selectively inhibits P‐glycoprotein (P‐gp) in t‐lymphocytes compared to that in the blood‐brain barrier (BBB) (2005) (1)
pharmacokinetic consequences Polymorphism of propafenone metabolism and disposition in man: clinical and (2011) (1)
Prediction of midazolam (MDZ) clearance (CL) using minimized sampling (MS) of 1-OHM and 1-OHM/MDZ in healthy subjects (HS) (2001) (1)
Tacial differences of Midazolam clearance. Comparison of Japanese and white races. (1998) (0)
Reduction of Liver Blood Flow and Propranolol Metabolism by Cimetidine (1981) (0)
Plasma Binding, Distribution, and Elimination (2020) (0)
Lack of genotype: phenotype associations between CYP3A4*1B, CYP3A5*3C, CYP3A5*6 and midazolam metabolism in european‐ and african‐americans (2003) (0)
Recurrence of bladder cancer is associated with cytocjrome P450llD6 debrisoquine 4-hydroxylase activity (1991) (0)
DRUG DISPOSITION: HEMODYNAMIC CONSIDERATIONS (1975) (0)
Cytochrome P450IIIA-mediated hydroxylation of dapsone in normal subjects and cirrhotics (1990) (0)
Lack of genotype: phenotype associations between CYP3A4*1B, CYP3A5*3C, CYP3A5*6 and midazolam metabolism in european‐ and african‐americans (2003) (0)
Suppression of Ventricular Ectopic Depolarizations (2005) (0)
2897 – THE INFLUENCE OF CIRRHOSIS ON FREE PROPRANOLOL CONCENTRATION DURING CHRONIC ORAL ADMINISTRATION (1978) (0)
Usefulness of Dextromethorphan as in vivo CYP3A active index drugs. (1997) (0)
The pharmacogenetics of bladder cancer Hydroxylation pathways and cytochrome P450 activity (1993) (0)
DIRECTMEASUREMENTOF PROPRANOLOLBIOAVAILABILITY DURINGACCUMULATIONTO STEADY-STATE (1978) (0)
Pyridoxal 5′-Phosphate (Plp) (2009) (0)
LIVER PHYSIOLOGY AND DISEASE ABNORMAL REGULATION OF PLASMA PYRIDOXAL 5'·PHOSPHATE IN PATIENTS WITH LIVER DISEASE (1976) (0)
Proceedings: Pharmacokinetics of diazepam in man. (1974) (0)
Correlation between the CYP3A‐mediated oral clearances of alprazolam, midazolam and triazolam (2004) (0)
The pharmacokinetics and clinical importance of polymorphic drug oxidation (1990) (0)
OIV‐B‐1 (2006) (0)
DRUG METABOLISM AND INTERINDIVIDUAL DIFFERENCES IN DRUG RESPONSIVENESS (1992) (0)
Molecular cloning, genomic organization, and tissue distribution of the human MRP3 transporter and its splice variants (1999) (0)
Deuterium labelling of the antidepressant drug doxepin for disposition studies in human subjects (1990) (0)
PHARMACOKINETICS OF THE FIRST PASS EFFECT (1976) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Grant R. Wilkinson?

Grant R. Wilkinson is affiliated with the following schools:

Grant R. Wilkinson's Academic­Influence.com Rankings

Grant R. Wilkinson's Degrees

Why Is Grant R. Wilkinson Influential?

Grant R. Wilkinson's Published Works

Published Works

What Schools Are Affiliated With Grant R. Wilkinson?

Grant R. Wilkinson's AcademicInfluence.com Rankings